Clinical Trials
90 trialsNeoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Institutes of Health Clinical Center (CC)
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
A First-in-Human Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of KUP-101A in Patients With Selected Advanced Solid Tumors
Kupando GmbH
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
LauT1
Centre Hospitalier Universitaire Vaudois
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
A Study of BI 3810944 in Patients With Advanced Cancer
Boehringer Ingelheim
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Valo Therapeutics Oy
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
A Study of CRD3874-SI in People With Solid Tumors
Memorial Sloan Kettering Cancer Center
A Study of DXC014 in Patients With Advanced Solid Tumors.
Hangzhou DAC Biotechnology Co., Ltd.
TRIUMPH
St Vincent's Hospital, Sydney
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
Pfizer
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
West Virginia University
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Pliant Therapeutics, Inc.
NST-628
Nested Therapeutics, Inc
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
University of Alabama at Birmingham
STEALTH-001
KaliVir Immunotherapeutics
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
H. Lee Moffitt Cancer Center and Research Institute
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
ANCHOR
Ankyra Therapeutics, Inc
IDOV-Immune for Advanced Solid Tumors
ViroMissile, Inc.
Asher-BioAB821
Yale University
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Ohio State University Comprehensive Cancer Center
Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases
Icahn School of Medicine at Mount Sinai
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Memorial Sloan Kettering Cancer Center
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Blue-Light Photodynamic Therapy and Sonidegib for Multiple Basal Cell Carcinomas
US Dermatology Partners, Phoenix